TRANSTHERA-B's stock fell sharply by 5.70% during intraday trading on Wednesday.
The decline followed the release of clinical data for the company's core product tiengoitinib, presented at the 2026 ASCO Gastrointestinal Cancers Symposium. Market participants may have engaged in a "sell-the-news" reaction to the data disclosure.
Additionally, the broader biotechnology sector showed weakness, contributing to the downward pressure on TRANSTHERA-B shares. The company remains in early-stage clinical development with pre-revenue status and reported significant net losses in its recent financial results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments